Navigation Links
A Better Acetabular Solution from StelKast ... Naturally
Date:4/15/2011

MCMURRAY, Pa., April 15, 2011 /PRNewswire/ -- StelKast is proud to announce the recent FDA 510(k) clearance of their new EXp™ Acetabular Liners. EXp™, a blend of antioxidant and highly cross-linked polyethylene technology was developed with the consulting support of Steven Kurtz, Ph.D. and Exponent, Inc. (Philadelphia, PA). StelKast has also received 510(k) clearance for large diameter cobalt-chrome femoral heads and Biolox® delta femoral heads.

(Logo:  http://photos.prnewswire.com/prnh/20110415/LA83876LOGO)

Mr. Peter Stephans, Chairman & CEO, said in a statement, "EXp™ polyethylene technology represents an optimal blend of UHMWPE, the antioxidant vitamin E (alpha-tocopherol), and cross-linking for long-term oxidative stability, preservation of mechanical properties and performance. Unlike other highly cross-linked materials, EXp™ polyethylene requires no thermal processing or infusion of antioxidants to stabilize the material. The combination of EXp™ Acetabular Liners and large diameter heads promotes joint stability.

"StelKast is excited to be the first US orthopedic company to provide a highly crosslinked vitamin E blended acetabular system offering superior oxidation resistance. The introduction of EXp™ polyethylene is just another example of StelKast's commitment to place emerging technology and high quality implants in surgeon's hands through cost effective solutions."

Full commercial launch of the EXp™ Acetabular System is planned for July 2011. For inquiries, please contact your local StelKast representative or Customer Service at 888-273-1583.

StelKast specializes in the design, manufacture, and distribution of hip and knee implant systems. The Company's mission is to provide high-quality, cost effective solutions to meet the challenges of the orthopedic community through clinically proven design concepts and innovative technology. For more information about StelKast, please visit the company website at www.stelkast.com.

Source: StelKast Inc.
Ph 888.273.1583
Fax 724.941.5987
200 Hidden Valley Road
McMurray, PA 15317 USA
www.stelkast.com


'/>"/>
SOURCE StelKast Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
2. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
3. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
6. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
7. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2016  The Addiction Treatment Advisory Group (ATAG), ... Care Pharmacy (AMCP), has released detailed findings on ... opioid addiction crisis, including through improved access to ... ATAG,s newly released paper, "The Role of Managed ... many issues around gaps and barriers to addiction ...
(Date:12/2/2016)... Dec. 2, 2016 Boston Scientific Corporation (NYSE: ... to acquire certain manufacturing assets and capabilities of the ... advanced biological tissue business, as well as a 15% ... million in cash. The Neovasc advanced biological tissue business ... Boston Scientific Lotus™ Valve System. * Upon completion ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional ... Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to extend ... , The demand for supplemental training related to pain management has surged dramatically ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Hour Power of Water, Global Climate Change and Your Health radio program syndicated ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... announce that they now offer a comprehensive in-house dental plan for all patients. ... have developed a plan that gives patients a number of perks, including discounts ...
Breaking Medicine News(10 mins):